Georgia's Online Cancer Information Center

Esophogeal Cancer Clinical Trials in Georgia

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.
Cancer Type = Esophogeal Cancer
Cancer Type = Esophogeal Cancer
There are currently 6 active Esophogeal Cancer clinical trials in Georgia.
1.
Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer
Cancer Type
Esophogeal Cancer, Unknown Primary
NCT ID
NCT03801876
Protocol IDs
NRG-GI006
NRG-GI006
NCI-2018-03378
2.
Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab
Cancer Type
Breast Cancer, Cervical Cancer, Esophogeal Cancer, Head and Neck Cancer, Hodgkin Lymphoma, Lung Cancer, Lymphoma, Stomach/ Gastric Cancer
NCT ID
NCT03674567
Protocol IDs
FLX475-02
NCI-2019-00102
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
3.
First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)
Cancer Type
Breast Cancer, Cervical Cancer, Colon/Rectal Cancer, Esophogeal Cancer, Lung Cancer, Ovarian Cancer, Stomach/ Gastric Cancer
NCT ID
NCT03401385
Protocol IDs
DS1062-A-J101
NCI-2018-01200
173812
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
4.
NCORP Trial
Nivolumab and Ipilimumab in Treating Patients with Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery
Cancer Type
Esophogeal Cancer
NCT ID
NCT03604991
Protocol IDs
EA2174
NCI-2018-01575
EA2174
Treatment Sites (2)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
5.
NCORP Trial
Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Cancer Type
Adrenal Cancer, Bile Duct Cancer, Bladder Cancer, Bone Tumor, Brain Tumor, Cervical Cancer, Colon/Rectal Cancer, Esophogeal Cancer, Gallbladder Cancer, Gastrointestinal Stromal Tumor (GIST), Germ Cell Tumor, Gestational trophoblastic disease, Gynecologic Cancers, Head and Neck Cancer, Liver Cancer / Hepatoblastoma, Lung Cancer, Mesothelioma, Neuroendocrine Tumor, Ovarian Cancer, Parathyroid Cancer, Penile Cancer, Retroperitoneal Tumors, Sarcoma, Small Bowel Cancer, Solid Tumor, Stomach/ Gastric Cancer, Testicular Cancer, Thyroid Cancer, Unknown Primary, Ureter Cancer, Urethral Cancer
NCT ID
NCT02834013
Protocol IDs
S1609
NCI-2016-01041
Treatment Sites (10)
Atlanta VA Medical Center
Decatur
Scott Edelman
404-728-7680
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Harbin Clinic Cancer Center
Rome
Dilawar Khan, MD
706-528-9110
Pearlman Cancer Center at South Georgia Medical Center
Valdosta
Jeffrey Hoy
229-259-4628
Piedmont Fayette Hospital
Fayetteville
404-851-2340
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
6.
Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC
Cancer Type
Esophogeal Cancer
NCT ID
NCT04550260
Protocol IDs
D910SC00001
NCI-2021-11850
Georgia CORE

 

Advancing Cancer Care through Partnerships and Innovation

Georgia CORE is a statewide nonprofit that leverages partnerships and innovation to attract more clinical trials, increase research, and promote education and early detection to improve cancer care for Georgians in rural, urban, and suburban communities across the state.